Reprogramming Cancer, Decoding DNA: Two Promising New Frontiers in Cancer Research

Two important scientific developments, published last week, offer a glimpse of where prostate cancer research could be heading, even though both remain firmly in the experimental or preclinical arena.

The first comes from Adelaide University, where researchers have developed “smart” lipid nanoparticles designed to reprogramme tumour-associated macrophages, immune cells that cancers can exploit to suppress an immune response. The nanoparticles target TREM2-positive macrophages and deliver mRNA encoding CXCL9, a signal that attracts cancer-killing CD8+ T cells, together with the immune-stimulating drug resiquimod. In mice, the approach reduced suppressive macrophages by more than 60%, increased CXCL9 fourfold and brought more active T cells into tumours, with a moderate reduction in tumour growth.

This is potentially interesting for prostate cancer because one of the major obstacles to successful immunotherapy is its often “cold” and immunosuppressive tumour environment. Rather than directly attacking cancer cells, approaches like this could eventually help remodel that environment so the immune system has a better opportunity to fight the disease. Importantly, however, the nanoparticle results are from animal experiments and are not yet evidence of effectiveness in prostate cancer patients.

At the same time, Google DeepMind has released AlphaGenome Atlas, an AI-powered resource containing predictions for the molecular effects of more than nine billion possible single-letter changes across the human genome. Particularly significant is its ability to investigate both protein-coding DNA and the much larger non-coding genome, where many disease-associated genetic variants are found. Researchers can use its AlphaGenome Variant Impact score to identify potentially important variants and investigate how they might alter processes such as gene expression, RNA splicing and chromatin regulation.

For prostate cancer researchers, this creates a potentially powerful discovery tool. It could help narrow enormous numbers of genetic variants to those most likely to influence prostate cancer susceptibility, tumour behaviour or biological pathways that might eventually become therapeutic targets.

Source1.

Source2.